Oxford scientists are to launch a major global trial to investigate whether cannabidiol (CBD) can treat people with psychosis or psychotic symptoms. The international study will involve 35 centres, mainly in Europe and North America. It will be coordinated by the University of Oxford’s department of psychiatry, which has been awarded £16.5m by the charitable foundation Wellcome. Read the article here.